Skip to main content
Fig. 5 | Cancer Cell International

Fig. 5

From: SOX17 increases the cisplatin sensitivity of an endometrial cancer cell line

Fig. 5

SOX17 influenced the sensitivity of tumor cells to cisplatin in vivo. The mice were inoculated with HEC-1B or HEC-1B-SOX17 cells and given saline (control group) or cisplatin (treatment group). a The tumors of HEC-1B-SOX17-treated cells were smaller than those of the HEC-1B-treated group. b Tumor growth curves of HEC-1B-treated cells (left) and of HEC-1B-SOX17-treated cells (right). The data are presented as the mean ± SD of five tumors per group. c The comparison of the cisplatin-induced growth inhibition of tumors from the two groups (*P < 0.05, **P < 0.001). d, e A higher apoptosis rate was exhibited in HEC-1B-SOX17-treated endometrial cancer cells than that in HEC-1B-treated cells as determined by TUNEL analysis (*P < 0.05). f Western blot analysis showing an elevated expression of p53, Bax and cleaved caspase-3 proteins in HEC-1B-SOX17-treated cells

Back to article page